Myriad Genetics (MYGN) Other Operating Expenses (2009 - 2026)

Myriad Genetics (MYGN) has reported Other Operating Expenses for 18 consecutive years, with $79.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Operating Expenses rose 14.16% year-over-year to $79.0 million; the TTM figure through Mar 2026 stood at $563.7 million (up 39.32% YoY), while the FY2025 annual figure was $600.2 million, up 87.8% from the prior year.
• Other Operating Expenses improved to $79.0 million in Q1 2026 per MYGN's latest filing, from $71.4 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $342.3 million in Q2 2025 and bottomed at -$56.5 million in Q4 2022.
• Historically, Other Operating Expenses has averaged $88.1 million across 5 years, with a median of $71.0 million in 2025.
• Annual changes were most pronounced in 2022 — Other Operating Expenses plunged 152.41% — and 2025, when it surged 784.5%.
• Myriad Genetics' Other Operating Expenses stood at -$56.5 million in 2022, then surged by 304.6% to $115.6 million in 2023, then jumped by 94.29% to $224.6 million in 2024, then sank by 68.21% to $71.4 million in 2025, then advanced by 10.64% to $79.0 million in 2026.
• Business Quant data shows MYGN's Other Operating Expenses at $79.0 million in Q1 2026, $71.4 million in Q4 2025, and $71.0 million in Q3 2025.